Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Ibrexafungerp bulk supplier for pharma manufacturers

Ibrexafungerp 150 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 150 mg

Reference Brands: Brexafemme (USA)

Category: Anti-fungal

Ibrexafungerp is a novel oral antifungal medication that works by inhibiting (1,3)-β-D-glucan synthase, an enzyme vital for fungal cell wall synthesis. Marketed as Brexafemme in the USA, it offers the first new oral antifungal class in over 20 years. It is primarily used to treat and prevent vulvovaginal candidiasis (yeast infections) caused by Candida species.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Ibrexafungerp — third party manufacturing & bulk supply

Ibrexafungerp 150 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ibrexafungerp is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ibrexafungerp listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ibrexafungerp →
Back to Listing

Frequently Asked Questions

Ibrexafungerp is used to treat vulvovaginal candidiasis (VVC), a vaginal yeast infection, in adult and post‑menarchal adolescent females. It is also used to reduce the chance of recurrent vulvovaginal candidiasis (RVVC).

Ibrexafungerp is a triterpenoid antifungal compound that works by inhibiting β‑1,3‑D‑glucan synthase, an enzyme essential for fungal cell‑wall synthesis. This weakens the fungal cell wall and leads to fungal death.

The trade name of Ibrexafungerp is Brexafemme.

Ibrexafungerp (Brexafemme) is manufactured by SCYNEXIS, Inc.

The generic name is ibrexafungerp.

The brand name is Brexafemme.

Ibrexafungerp is manufactured by SCYNEXIS, Inc., and is available in certain markets as an oral tablet under the brand Brexafemme.

Related Products

Ciclopirox

Strength:
0.77%

Form: Creams/ Gel/ Lotion

Reference Brands: Loprox (USA), Penlac (USA/EU)

View Details
Econazole Nitrate

Strength:
1%

Form: Creams / Foam

Reference Brands: Ecoza (USA), Pevaryl (EU/UK) , Spectazole (USA)

View Details
Sertaconazole Nitrate

Strength:
2 %

Form: Creams

Reference Brands: Ertaczo (USA), Zalain (EU)

View Details
Miltefosine

Strength:
10 mg, 50 mg

Form: Capsules

Reference Brands: Impavido (USA/EU)

View Details
Nystatin Topical Creams And Ointments

Strength:
100,000 units/g, 100,000–300,000 units/g

Form: Topical Creams and Ointments

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details
Nystatin Oral Suspensions/Tablets

Strength:
Tab: 500,000 units, 1,000,000 units; Sus: 100,000 units/mL, 500,000 units/5 mL

Form: Tablets/Suspensions

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details
Naftifine Hydrochloride

Strength:
1 %, 2%

Form: Cream / Gel

Reference Brands: Naftin (USA), Xolafin (USA)

View Details
Natamycin

Strength:
5%

Form: Ophthalmic Solution

Reference Brands: Natacyn (USA/EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.